Personalis Inc (PSNL) Q4 2025 Earnings Call Highlights: Robust Clinical Growth Amidst Revenue ... [Yahoo! Finance]
Personalis, Inc. (PSNL)
Last personalis, inc. earnings: 3/25 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Release Date: February 26, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Personalis Inc ( NASDAQ:PSNL ) achieved significant clinical growth with a 329% year-over-year increase in clinical tests delivered in Q4 2025. The company secured two Medicare coverage decisions for breast and lung cancer, validating the value of their MRD technology. Personalis Inc ( NASDAQ:PSNL ) reported a 239% growth in biopharma MRD revenue over the prior year, indicating strong demand for their services. The company has a strong cash position with $240 million in cash and short-term investments, providing a solid financial foundation. Personalis Inc ( NASDAQ:PSNL ) is expanding its commercial footprint with plans to double its sales representatives to drive further growth. Negative Points Personalis Inc ( NASDAQ:PSNL ) experienced a planned $19.5 million decline in revenu
Show less
Read more
Impact Snapshot
Event Time:
PSNL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSNL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSNL alerts
High impacting Personalis, Inc. news events
Weekly update
A roundup of the hottest topics
PSNL
News
- Personalis (PSNL) had its price target lowered by Morgan Stanley from $11.00 to $10.00. They now have an "equal weight" rating on the stock.MarketBeat
- Personalis (PSNL) had its price target raised by Needham & Company LLC from $10.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Personalis outlines 170% clinical test volume growth target for 2026 as reimbursement and MRD strategy accelerate [Seeking Alpha]Seeking Alpha
- Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Personalis GAAP EPS of -$0.26 beats by $0.03, revenue of $17.35M beats by $0.23M [Seeking Alpha]Seeking Alpha
PSNL
Earnings
- 2/26/26 - Beat
PSNL
Sec Filings
- 2/26/26 - Form S-8
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- PSNL's page on the SEC website